Earnings ·
Dr. Reddy's Laboratories reported Q1 FY27 consolidated revenues of ₹8,071 crores (US$853 million), a 5.6%…
RDYDR Reddys Laboratories Ltd
Dr. Reddy's Laboratories reported Q1 FY27 consolidated revenues of ₹8,071 crores (US$853 million), a 5.6% year-over-year decline driven by lower lenalidomide sales and a ₹240 crore provision for semaglutide API-related challenges. The company recorded an EBITDA margin of 12.5%, though underlying margins excluding the provision were 15.4%. Management plans to resume semaglutide commercial supplies in November, targeting 6-7 million pens between November and March. The US FDA issued a Form 483 with seven observations at the Bachupally biologics facility, which have been addressed; the abatacept BLA goal date remains mid-December 2026. Dr. Reddy's Laboratories Limited operates in the pharmaceutical industry, developing and manufacturing generic drugs, biosimilars, and active pharmaceutical ingredients.